Cargando…
Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
BACKGROUND: Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. METHODS: Proteomic analysis of the human...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346861/ https://www.ncbi.nlm.nih.gov/pubmed/32704452 http://dx.doi.org/10.7717/peerj.9507 |
_version_ | 1783556480703660032 |
---|---|
author | Li, Dandan Wu, Jie Liu, Zhongjuan Qiu, Ling Zhang, Yimin |
author_facet | Li, Dandan Wu, Jie Liu, Zhongjuan Qiu, Ling Zhang, Yimin |
author_sort | Li, Dandan |
collection | PubMed |
description | BACKGROUND: Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. METHODS: Proteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). In addition, 15 patients with benign thyroid nodules (TNs) and 10 healthy controls (HCs) were included in this study. Subsequently, 17 differentially expressed proteins were identified in 291 patients with TC, including 247 with PTC, 38 with MTC, and six with FTC, and 69 patients with benign TNs and 176 with HC, using enzyme-linked immunosorbent assays. RESULTS: In total, 517 proteins were detected in the serum samples using an Orbitrap Q-Exactive-plus mass spectrometer. The amyloid beta A4 protein, apolipoprotein A-IV, gelsolin, contactin-1, gamma-glutamyl hydrolase, and complement factor H-related protein 1 (CFHR1) were selected for further analysis. The median serum CFHR1 levels were significantly higher in the MTC and FTC groups than in the PTC and control groups (P < 0.001). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL. CONCLUSION: CFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity. |
format | Online Article Text |
id | pubmed-7346861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73468612020-07-22 Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry Li, Dandan Wu, Jie Liu, Zhongjuan Qiu, Ling Zhang, Yimin PeerJ Bioinformatics BACKGROUND: Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. METHODS: Proteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). In addition, 15 patients with benign thyroid nodules (TNs) and 10 healthy controls (HCs) were included in this study. Subsequently, 17 differentially expressed proteins were identified in 291 patients with TC, including 247 with PTC, 38 with MTC, and six with FTC, and 69 patients with benign TNs and 176 with HC, using enzyme-linked immunosorbent assays. RESULTS: In total, 517 proteins were detected in the serum samples using an Orbitrap Q-Exactive-plus mass spectrometer. The amyloid beta A4 protein, apolipoprotein A-IV, gelsolin, contactin-1, gamma-glutamyl hydrolase, and complement factor H-related protein 1 (CFHR1) were selected for further analysis. The median serum CFHR1 levels were significantly higher in the MTC and FTC groups than in the PTC and control groups (P < 0.001). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL. CONCLUSION: CFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity. PeerJ Inc. 2020-07-06 /pmc/articles/PMC7346861/ /pubmed/32704452 http://dx.doi.org/10.7717/peerj.9507 Text en © 2020 Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Bioinformatics Li, Dandan Wu, Jie Liu, Zhongjuan Qiu, Ling Zhang, Yimin Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
title | Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
title_full | Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
title_fullStr | Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
title_full_unstemmed | Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
title_short | Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
title_sort | novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry |
topic | Bioinformatics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346861/ https://www.ncbi.nlm.nih.gov/pubmed/32704452 http://dx.doi.org/10.7717/peerj.9507 |
work_keys_str_mv | AT lidandan novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry AT wujie novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry AT liuzhongjuan novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry AT qiuling novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry AT zhangyimin novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry |